HopeMed Hopes For First-Line Inroads In Endometriosis-Associated Pain

 
• By Dexter Jie Yan

Interim results from an international Phase II study with its prolactin inhibiting antibody have boosted HopeMed’s confidence in its first-line potential in the chronic disorder, the Chinese venture's CEO tells Scrip.

Women's health
Hope Medicine hopes its HMI-115, a prolactin inhibitor, could tackle endometriosis-associated pain in the first-line setting. • Source: Shutterstock

More from R&D

More from Scrip